Устранение неизбежности аллергического ответа

аллерген-специфическая иммунотерапия, аллергические заболевания, тимический стромальный лимфопоэтин TSLP, иммуноглобулин Е, цитокины, Th2-клетки, рецепторы

1. Asher M.I., Montefort S., Bjorksten B. et al. Wordwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733-743.

2. Floistrup H., Swartz J., Bergstrom A. et al. Allergic disease and sensitization in Steiner school children. J. Allergy Clin. Immunol. 2006; 117: 59-66.

3. van Schayck C.P., Smit H.A. The prevalence of asthma in children: a reversing trend. Eur. Respir. J. 2005; 26: 647-650.

4. Ponsonby A.L., Glasgow N., Pezic A. et al. A temporal decline in asthma but not eczema prevalence from 2000 to 2005 at school entry in the Australian Capital Territory with further consideration of country of birth. Int. J. Epidemiol. 2008; 37: 559-569.

5. Anandan C., Nurmatov U., van Schayck O.C.P., Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010; 65: 152-167.

6. Gell P.G.H., Coombs R.P.A. Clinical aspects of immunology. Philadelphia: F.A.Davis Co.; 1964.

7. Blaser K. Role of T!cell subtypes in allergic inflammation. Chem. Immunol. Allergy 2008; 94: XI-XV.

8. Miller R.L. Prenatal maternal diet affects asthma risk in offspring. J. Clin. Invest. 2008; 118: 3265-3268.

9. Miller R.L., Ho S.M. Environmental epigenetics and asthma: current concepts and call for studies. Am. J. Respir. Crit. Care Med. 2008; 177: 567-573.

10. Martino D.J., Prescott S.L. Silent mysteries: epigenetic paradigms could hold the key to conquering the epidemic of allergy and immune disease. Allergy 2010; 65: 7-15.

11. Гущин И.С. Немедленная аллергия клетки. М.: Медицина; 1976.

12. Гущин И.С. Об элементах биологической целесообразности аллергической реактивности. Пат. физиол. 1979; 4: 3-11.

13. Гущин И.С. Преодоление аллергеном тканевого барье ра - решающая форма предрасположения к аллергии. Пат. физиол. 2009; 1: 8-13.

14. Ярилин А.А. TSLP (лимфопоэтин из стромы тимуса) - новый патогенетический фактор аллергии. Рос. аллер гол. журн. 2008; 5: 9-13.

15. Rochman Y., Leonard W. Thymic stromal lymphopoietin: a new cytokine in asthma. Curr. Opin. Pharmacol. 2008; 8: 249-253.

16. Wang Y.H., Liu Y.J. Thymic stromal lymphopoietin, OX40- ligand and interleukin-25 in allergic responses. Clin. Exp. Allergy 2009; 39: 798-806.

17. Liu Y. TSLP in epithelium cell and dendritic cell cross talk. Adv. Immunol. 2009; 101: 1-25.

18. Wang Y.H., Liu Y.J. OX40-OX40L interactions: a promising therapeutic target for allergic diseases? J. Clin. Invest. 2007; 117: 3655-3657.

19. Zhang Z., Hener P., Frossard N. et al. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc. Natl. Acad. Sci. USA 2009; 106: 1536-1541.

20. Gould H.J., Sutton B.J., Beavil A.J. et al. The biology of IgE and the basis of allergic disease. Annu. Rev. Immunol. 2003; 21: 579-628.

21. Vangelista L. Curent progress in understanding of IgE FcεRI interaction. Int. Arch. Allergy Immunol. 2003; 131: 222-233.

22. Гущин И.С. Взаимодействие IgE с FcεRI как объект ан тиаллергического воздействия. Рос. аллергол. журн. 2005; 1: 7-18.

23. Rindsjo E., Joerink M., Papadogiannakis N., Scheynius A. IgE in the human placenta: why there? Allergy. 2010; 65: 554-560.

24. Forth Edition. Lockey R.F., Ledfprd D.K., eds. Allergens and allergen immunotherapy. New York: Marcel Dekker, Inc; 2008.

25. Rolland J.M., Gardner L.M., O'Hehir R.E. Allergen-related approaches to immunotherapy. Pharmacol. Ther. 2009; 121: 273-284.

26. Гущин И.С., Курбачева О.М. Аллерген-специфическая иммунотерапия атопических заболеваний. (Пособие для врачей). М.; 2002.

27. Сiprandi G., De Amici M., Tosca M.A. et al. Sublingual immunotherapy affects specific antibody and TGF!beta serum levels in patients with allergic rhinitis. Int. J. Immunopathol. 2009; 22: 1089-1096.

28. Scadding G.W., Shamji M.H., Jacobson M.R. etal. Sub lingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressory cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B-cells. Clin. Exp. Allergy 2010; 40: 598-606.

29. Tsai J.J., Liao E.C., Tsai F.H. et al. The affect of local nasal immunotherapy in allergic rhinitis: using strips of the aller gen dermatophagoides pteronossinus. J. Asthma 2009; 46: 165-170.

30. Till S.J., Durham S.R. Immunological responces to allergen immunotherapy. In: Lockley R.F., Bukantz S.C., Bousquet J. Allergen and allergen immunotherapy. 3rd Ed. Revised and expanded. New York: Marcell Dekker, Inc.; 2004. 85-98.

31. Pipet A., Botturi K., Pinot D. et al. Allergen-specific immu notherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir. Med. 2009; 103: 800-812.

32. Nouri-Aria K.T., Wachholz P.A., Francis J.N. et al. Grass pollen immunotherapy induces mucosal and peripheral IL 10 responses and blocking IgG activity. J. Immunol. 2004; 172: 3252-3259.

33. Radulovic S., Jacobson M.R., Durham S.R., Nouri1Aria K.T. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J. Allergy Clin. Immunol. 2008; 121: 1467-1472.